CD133 was first discovered as a surface antigen on CD34+ hematopoietic stem cells [2] and has been used in combination with other cell-surface markers, including CD24, CD34, and CD44, to isolate cancer stem cells (CSCs) from a variety of tumors [3]. Here, CD34 is linked to cancer.